Advertisement

Search Results

Advertisement



Your search for The,The matches 29622 pages

Showing 101 - 150


solid tumors

Randomized Phase II Trial Shows Benefits of Prophylactic Radiation Therapy for Asymptomatic Bone Metastases

The use of prophylactic radiation therapy for patients with metastatic cancer who had asymptomatic, high-risk bone metastases reduced the incidence of skeletal-related events, reduced pain and the number of hospitalizations, and was associated with significantly longer overall survival compared...

breast cancer
genomics/genetics

Prophylactic Bilateral Mastectomy Among Women With Breast Cancer and Pathogenic Variants in High-Penetrance and Moderate-Penetrance Genes

In a study reported in JAMA Oncology, Reid et al found that undergoing prophylactic bilateral mastectomy was as common in women with breast cancer with pathogenic/likely pathogenic variants in ATM and CHEK2 (moderate-penetrance genes) as in those with variants in BRCA1, BRCA2, or PALB2...

solid tumors
immunotherapy

Antoni Ribas, MD, PhD, on Solid Tumors: Safety and Efficacy of TCR T-Cell Therapy

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, discusses a phase I study that used CRISPR gene editing to simultaneously “knock out” endogenous T-cell receptors and replace them with personalized neoantigen T-cell receptors in patients with solid tumors. The edited TCR T-cell...

immunotherapy

Michael A. Postow, MD, on Using the Novel Radiotracer Crefmirlimab Berdoxam for Imaging to Assess Immunotherapy Responsiveness

Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings on the correlation between CD8 cell PET imaging with zirconium-89–crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy. Noninvasive CD8 PET scanning...

cns cancers
immunotherapy

David Reardon, MD, on Glioblastoma: A Microbiome-Based Vaccine, Nivolumab, and Bevacizumab

David Reardon, MD, of Dana-Farber Cancer Institute, discusses phase I/II results from the EOGBM1-18/ROSALIE study, which showed the EO2401 vaccine plus nivolumab generated systemic immune responses correlating with efficacy in patients with recurrent glioblastoma. Adding bevacizumab to this...

lung cancer
immunotherapy

Wade T. Iams, MD, on NSCLC: Combining an Antigen-Presenting Cell Activator With Pembrolizumab

Wade T. Iams, MD, of Vanderbilt University Medical Center, discusses phase II efficacy results from the first-line non–small cell lung cancer cohort of the TACTI-002 study. The results suggest that when combined with pembrolizumab, eftilagimod alpha yielded encouraging efficacy across all PD-L1...

hepatobiliary cancer

Futibatinib for Cholangiocarcinoma With FGFR2 Gene Fusion or Other Rearrangements

On September 30, 2022, futibatinib was granted accelerated approval for adults with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.1 Supporting Efficacy ...

supportive care

Sodium Thiosulfate to Reduce the Risk of Cisplatin-Related Ototoxicity in Pediatric Patients With Localized Solid Tumors

On September 20, 2022, sodium thiosulfate was approved to reduce the risk of ototoxicity associated with cisplatin in pediatric patients (aged ≥ 1 month) with localized, nonmetastatic solid tumors.1 Supporting Efficacy Data Approval was based on findings in the multicenter open-label SIOPEL 6...

lung cancer

Selpercatinib Approved for Advanced RET Fusion–Positive Solid Tumors and Advanced RET Fusion–Positive NSCLC

On September 21, 2022, selpercatinib was granted accelerated approval for adults with locally advanced or metastatic solid tumors with RET gene fusion whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.1 On the same day,...

lung cancer

2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives

The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined ...

breast cancer

Used as a Biomarker, MicroRNA May Help Predict Which Patients With Breast Cancer Are More Likely to Have Cancer Recurrence

MicroRNA may be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality, according to a new study published by Davey et al in the Journal of the American College of Surgeons. While long-term outcomes have improved for patients with breast cancer, 20%...

hepatobiliary cancer

Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer

On September 2, 2022, durvalumab was approved for use in combination with gemcitabine/cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on findings in the double-blind TOPAZ-1 trial (ClinicalTrials.gov...

immunotherapy
lung cancer

Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors

Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living with HIV and metastatic non–small cell lung cancer, who are often underrepresented in clinical...

kidney cancer

Prevalence of Tumor Thrombus at RCC Diagnosis and Risk of Venous Thromboembolism

In a Dutch single-institution retrospective cohort study reported in JACC: CardioOncology, Kaptein et al identified the prevalence of venous tumor thrombus at diagnosis in patients with renal cell carcinoma (RCC) and the associated risk of venous thromboembolism. Study Details The study included...

breast cancer

Addition of Fluorouracil to Adjuvant Chemotherapy and Comparison of Standard vs Dose-Dense Treatment in Node-Positive Early Breast Cancer

As reported in The Lancet Oncology by Lucia Del Mastro, MD, and colleagues, end-of-study findings from the Italian phase III GIM2 trial after a median follow-up of 15 years indicate that the addition of fluorouracil to adjuvant epirubicin, cyclophosphamide, and paclitaxel did not improve outcomes...

survivorship

Fracture Risk Among Older Cancer Survivors

In a study reported in JAMA Oncology, Rees-Punia et al found that the risk of frailty-related bone fractures among older cancer survivors was significantly greater vs that among older adults without a history of cancer. Study Details The longitudinal cohort study used data from 92,431 older adults...

multiple myeloma

Proposed Threshold for Circulating Tumor Plasma Cells to Define Plasma Cell Leukemia–Like Multiple Myeloma

In a study reported in the Journal of Clinical Oncology, Jelinek et al provided evidence that a threshold of ≥ 2% circulating tumor plasma cells (CTCs) defines the presence of plasma cell leukemia (PCL)-like multiple myeloma. As stated by the investigators, “Primary PCL is the most aggressive...

gynecologic cancers

New Research Highlights Disparities in Receipt of Guideline-Concordant Treatment Among Patients With Ovarian Cancer

New research examining whether patients with ovarian cancer were receiving care concordant with the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) found clear disparities based on patients’ race, ability to pay, and access to specialists and...

colorectal cancer

Nationwide Study Finds Higher Rates of Cancer Mortality, Increasing Cases of Early-Onset Colorectal Cancer Among American Indian and Alaska Native Individuals

New findings revealed that overall cancer mortality among American Indian and Alaska Native patients was 18% higher than among White patients despite similar cancer incidence, according to a new study published by Kratzer et al in CA: A Cancer Journal for Clinicians. The findings included the first ...

skin cancer

Researchers Identify Subset of Patients With Stage I Melanoma Who Have Low Risk of Melanoma Mortality

Researchers identified a subset of patients who had early-stage melanoma with almost no melanoma-related deaths, potentially representing cases contributing to overdiagnosis, according to a new study published by Eguchi et al in Cancer. The findings may help clinicians determine which patients have ...

issues in oncology

Cancer Clinical Trial Participation Among Medicare Fee-for-Service Beneficiaries With Cancer

In a retrospective cohort study reported in JAMA Oncology, Green et al found that only 1% to 2% of Medicare fee-for-service beneficiaries aged ≥ 65 years with cancer were enrolled in interventional cancer clinical trials. Study Details The study assessed clinical trial participation among patients...

gynecologic cancers

FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

On November 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received...

colorectal cancer

Early Discontinuation of Full Treatment Regimen or Oxaliplatin Alone in Patients Receiving Adjuvant Oxaliplatin/Fluoropyrimidine Therapy for Stage III Colon Cancer

In a pooled analysis reported in the Journal of Clinical Oncology, Gallois et al found that early discontinuation of adjuvant oxaliplatin/fluoropyrimidine regimens—consisting of  FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin) or CAPOX (capecitabine and oxaliplatin)—was associated...

skin cancer
immunotherapy

New Phase I/II Data on the CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma

New data from an ongoing phase II trial evaluating first-line intratumoral administration of sotigalimab, a CD40 agonist antibody, in combination with systemic pembrolizumab, an anti–PD-1 antibody, in metastatic melanoma was presented by Bentebibel et al at the Society for Immunotherapy of Cancer...

breast cancer
lymphoma
survivorship

Cost-Effectiveness of COG Breast Cancer Screening Guidelines for Hodgkin Lymphoma Survivors Who Received Chest Irradiation

In a cost-effective analysis reported in the Journal of Clinical Oncology, Wong et al found that only the mammography component of the Children’s Oncology Group (COG) breast cancer screening guidelines for chest-irradiated Hodgkin lymphoma survivors was cost-effective; magnetic resonance imaging...

skin cancer
immunotherapy

Management of Severe Immune-Related Adverse Events With Ipilimumab/Nivolumab and Survival in Advanced Melanoma

In a Dutch study reported in JAMA Oncology, van Not et al found that management of grade ≥ 3 immune-related adverse events with steroids alone vs steroids plus second-line immunosuppressants was associated with better survival outcomes among patients receiving first-line combination ipilimumab and...

colorectal cancer

Prevalence of Mismatch Repair Deficiency in Rectal Adenocarcinoma in a Prospective Screening Program

As reported in a letter published in The New England Journal of Medicine by Papke et al, data from a prospective biopsy screening program at a large gastrointestinal pathology group indicate that approximately 3% of rectal adenocarcinomas are mismatch repair (MMR)-deficient. Study Background As...

leukemia
genomics/genetics

Rare Germline ATM Variants in Chronic Lymphocytic Leukemia

In a single-institution analysis reported in the Journal of Clinical Oncology, Benjamin L. Lampson, MD, and colleagues found a higher prevalence of rare germline ATM variants in chronic lymphocytic leukemia (CLL) vs other lymphoid and myeloid disorders. They also determined that patients with CLL...

lung cancer
genomics/genetics
immunotherapy

First-Line Pembrolizumab vs Chemotherapy in Advanced PD-L1–Positive NSCLC Without EGFR/ALK Alterations

As reported in the Journal of Clinical Oncology by Gilberto de Castro, Jr, MD, PhD, and colleagues, 5-year follow-up of the KEYNOTE-042 trial showed a maintained overall survival benefit with first-line pembrolizumab vs chemotherapy in patients with non–small cell lung cancer (NSCLC) with a PD-L1...

lung cancer
immunotherapy

Immune Checkpoint Inhibitors for Patients Living With HIV: Safe and Effective in Metastatic NSCLC

Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented by El Zarif et al at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting (Abstract 437). Findings from the first matched...

multiple myeloma
immunotherapy

Potential Treatment Options for Patients With Relapsed Multiple Myeloma Following CAR T-Cell Therapy

Researchers have identified potential therapies to treat patients with multiple myeloma whose cancer has relapsed following chimeric antigen receptor (CAR) T-cell therapy, according to a novel study published by Van Oekelen et al in Blood. CAR T-cell therapy has been a revolutionary treatment for...

immunotherapy

Hormone Therapy May Lower Risk of Immune Checkpoint Inhibitor–Associated Myocarditis in Female Patients

Researchers may have discovered the underlying cause of sex differences in immune checkpoint inhibitor–associated myocarditis after immune checkpoint inhibitor treatment, according to a novel study published by Zhang et al in Science Translational Medicine. Their findings pointed to possible...

leukemia
survivorship

CNS-Directed Therapy and Neurocognitive Outcomes in Survivors of Childhood ALL Receiving No Cranial Irradiation

In a single-institution study reported in the Journal of Clinical Oncology, Jacola et al found that survivors of childhood acute lymphoblastic leukemia (ALL) who received central nervous system (CNS)-directed therapy excluding cranial irradiation had poorer outcomes in numerous neurocognitive...

sarcoma

Comparison of Two Chemotherapy Regimens for Newly Diagnosed Ewing Sarcoma

As reported in The Lancet by Brennan et al, the European phase III EURO EWING 2012 trial found improved event-free survival with a standard U.S. chemotherapy regimen vs a standard European regimen in newly diagnosed patients with Ewing sarcoma. As stated by the investigators, “Internationally, a...

lung cancer
immunotherapy

FDA Approves Tremelimumab in Combination With Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

On November 10, the U.S. Food and Drug Administration (FDA) approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) and platinum-based chemotherapy for adult patients with metastatic non–small cell lung cancer (NSCLC) with no EGFR mutations or ALK genomic tumor aberrations. ...

lymphoma
immunotherapy

FDA Approves Brentuximab Vedotin in Combination With Chemotherapy for Pediatric Patients With Classical Hodgkin Lymphoma

On November 10, the U.S. Food and Drug Administration (FDA) approved the CD30-directed antibody-drug conjugate brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide for pediatric patients aged 2 years and older with previously...

issues in oncology

My White Coat Doesn’t Fit

There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...

hepatobiliary cancer
immunotherapy

Expert Point of View: Robin Kate Kelley, MD

Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main takeaway is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to...

hepatobiliary cancer
immunotherapy

Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma: LEAP-002 Fails to Meet Co-primary Endpoints

The highly anticipated final analysis of the phase III LEAP-002 trial failed to meet expectations, as first-line treatment with lenvatinib plus pembrolizumab did not significantly improve outcomes in unresectable advanced hepatocellular carcinoma. Both progression-free survival and overall survival ...

head and neck cancer
immunotherapy

Expert Point of View: Glenn J. Hanna, MD, and Sherene Loi, MD, PhD

The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...

head and neck cancer
immunotherapy

KEYNOTE-412: Pembrolizumab Plus Chemoradiation Falls Short in Locally Advanced Head and Neck Cancer

Pembrolizumab plus chemoradiation failed to demonstrate a statistically significant improvement in event-free survival vs chemoradiation alone in patients with locally advanced head and neck squamous cell carcinoma, but favorable numerical trends were demonstrated, according to results of the phase ...

Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology

Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...

Eytan Stein, MD, Appointed Chief of the Leukemia Service at MSK

Eytan M. Stein, MD, will assume the role of Chief of the Leukemia Service in the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSK), New York. Dr. Stein joined MSK as a medical oncology/hematology fellow in 2010, became a faculty member in 2013, and was appointed...

SWOG Names Don S. Dizon, MD, Vice Chair for Diversity, Equity, Inclusion, and Professional Integrity

After nearly a year-long search, the Southwest Oncology Group (SWOG) has announced its new Vice Chair for Diversity, Equity, Inclusion (DEI), and Professional Integrity: Don S. Dizon, MD, who is currently Chair of the organization’s Digital Engagement Committee. Dr. Dizon is Director of the Pelvic...

colorectal cancer

Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...

breast cancer
immunotherapy

Expert Point of View: Shom Goel, MBBS, PhD

The invited discussant of the post hoc analysis of TROPiCS-02 was Shom Goel, MBBS, PhD, Laboratory Group Leader at the University of Melbourne and a consultant oncologist at the Peter MacCallum Cancer Centre in Australia. Dr. Goel noted there remains much to learn about the HER2-low subset of...

ASCO Releases Updated Resource-Stratified Guideline for the Secondary Prevention of Cervical Cancer

A new resource-stratified ASCO guideline update provides new evidence-based recommendations for the secondary prevention of cervical cancer in various resource settings.1 In the updated guideline, the screening recommendations cover basic, limited, enhanced, and maximal resource settings. Since...

breast cancer
immunotherapy

TROPiCS-02: Efficacy of Sacituzumab Govitecan Within HER2-Negative Subsets of Breast Cancer

In a post hoc analysis of the phase III TROPiCS-02 trial, sacituzumab govite­can-hziy improved efficacy outcomes in HER2-negative immunohistochemistry (IHC) subgroups.1 Results were consistent with those of the intent-to-treat population of hormone receptor–positive/HER2-negative advanced breast...

Study Sheds Light on Need for Optimal Dosing Standards for Patients With Metastatic Cancer

A new study, published recently in JCO Oncology Practice, found that oncologists have different perspectives on how to select starting doses for patients with metastatic cancer.1 The study shared findings from a 2021 international survey of 367 medical oncologists who treat patients with metastatic ...

lung cancer
immunotherapy

POSEIDON Follow-up Suggests Chemoimmunotherapy Triplet Extends Survival in Difficult-to-Treat NSCLC Mutational Subtypes

After 4 years, a limited course of five cycles of tremelimumab added to durvalumab plus chemotherapy extended overall survival in patients with metastatic non–small cell lung cancer (NSCLC) compared with chemotherapy alone, according to an updated exploratory analysis of the phase III POSEIDON...

Advertisement

Advertisement



Advertisement